# To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

> **NCT05514158** · PHASE1 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** RC48-ADC
- **DRUG:** RC98

## Key facts

- **NCT ID:** NCT05514158
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-28
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514158, "To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05514158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*